Triggering the TCR Developmental Checkpoint Activates a Therapeutically Targetable Tumor Suppressive Pathway in T-cell Leukemia - Archive ouverte HAL Access content directly
Journal Articles Cancer Discovery Year : 2016

Triggering the TCR Developmental Checkpoint Activates a Therapeutically Targetable Tumor Suppressive Pathway in T-cell Leukemia

(1) , (2, 3) , (3) , (3) , (3) , (4, 1) , (3) , (1) , (1) , (5) , (6) , (6, 7) , (8) , (9) , (10) , (4) , (1) , (11) , (5) , (1) , (12, 3) , (1, 13)
1
2
3
4
5
6
7
8
9
10
11
12
13
Ludovic Lhermitte
Hervé Dombret
Elizabeth Macintyre
  • Function : Author
  • PersonId : 902525

Abstract

Cancer onset and progression involves the accumulation of multiple oncogenic hits, which are thought to dominate or bypass the physiologic regulatory mechanisms in tissue development and homeostasis. We demonstrate in T-cell acute lymphoblastic leukemia (T-ALL) that, irrespective of the complex oncogenic abnormalities underlying tumor progression, experimentally induced, persistent T-cell receptor (TCR) signaling has antileukemic properties and enforces a molecular program resembling thymic negative selection, a major developmental event in normal T-cell development. Using mouse models of T-ALL, we show that induction of TCR signaling by high-affinity self-peptide/MHC or treatment with monoclonal antibodies to the CD3 epsilon chain (anti-CD3) causes massive leukemic cell death. Importantly, anti-CD3 treatment hampered leukemogenesis in mice transplanted with either mouse-or patient-derived T-ALLs. These data provide a strong rationale for targeted therapy based on anti-CD3 treatment of patients with TCR-expressing T-ALL and demonstrate that endogenous developmental checkpoint pathways are amenable to therapeutic intervention in cancer cells. SIGNIFICANCE: T-ALLs are aggressive malignant lymphoid proliferations of T-cell precursors characterized by high relapse rates and poor prognosis, calling for the search for novel therapeutic options. Here, we report that the lineage-specific TCR/CD3 developmental checkpoint controlling cell death in normal T-cell progenitors remains switchable to induce massive tumor cell apoptosis in T-ALL and is amenable to preclinical therapeutic intervention. (C) 2016 AACR.
Not file

Dates and versions

hal-01460133 , version 1 (07-02-2017)

Identifiers

Cite

Amélie Trinquand, Nuno R. Dos Santos, Christine Tran Quang, Francesca Rocchetti, Benedetta Zaniboni, et al.. Triggering the TCR Developmental Checkpoint Activates a Therapeutically Targetable Tumor Suppressive Pathway in T-cell Leukemia. Cancer Discovery, 2016, 6 (9), pp.972-985. ⟨10.1158/2159-8290.CD-15-0675⟩. ⟨hal-01460133⟩
223 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More